


#17

Substitute PTO/SB/8A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449A/PTO
(Modified)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

Complete if Known

Application Number 09/981,289
Filing Date October 15, 2001
First Named Inventor DAHIYAT, Bassil I.
Group Art Unit 1647
Examiner Name SEHARASEYON, J.
Attorney Docket Number A-68990-3 (463077-0009)

U.S. PATENT DOCUMENTS

| Examiner Initials* | Cite No. | U.S. Patent Document Number-Kind Code ² (if known) | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
|--------------------|----------|---|-----------------------------|---|---|
| | A1 | | | | |
| | A2 | | | | |
| | A3 | | | | |
| | A4 | | | | |
| | A5 | | | | |
| | A6 | | | | |
| | A7 | | | | |
| | A8 | | | | |
| | A9 | | | | |
| | A10 | | | | |

RECEIVED
APR 21 2003
TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS

| Examiner Initials* | Cite No. | Foreign Patent Document Country Code ² Number ⁴ Kind Code ⁵ (if known) | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁶ |
|--------------------|----------|---|-----------------------------|---|---|----------------|
| | B1 | | | | | |
| | B2 | | | | | |
| | B3 | | | | | |
| | B4 | | | | | |
| | B5 | | | | | |
| | B6 | | | | | |

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ⁶ |
|--------------------|----------|---|----------------|
| JS | C1 | LI, Y. et al., "PEGylated Recombinant Human Tumor Necrosis Factor Alpha: Pharmacokinetics and Anti-tumor Effects," Biol. Pharm. Bull. 24(6):666-670 (2001) | |
| | C2 | MENART, V, et al., "Early events in TNFa-p55 receptor interactions--experiments with TNF dimers." Pflugers Arch. 2000;439(3 Suppl):R113-5. | |
| | C3 | WILLIAMS-ABBOTT, L, et al., "The lymphotoxin-alpha (LTalpha) subunit is essential for the assembly, but not for the receptor specificity, of the membrane-anchored LTalpha1beta2 heterotrimeric ligand." J Biol Chem. 1997 Aug 1;272(31):19451-6. | |
| | C4 | NGO et al., "Computational Complexity, Protein Structure Prediction and the Levinthal Paradox, The Protein Folding Problem and Tertiary Structure Prediction, pp. 492-495 | |
| U | C5 | WELLS, Aditivity of Mutational Effects in Proteins, 1990, Biochemistry, 26(37):8509-8517 | |

| | | | |
|--------------------|--|-----------------|---------|
| Examiner Signature | | Date Considered | 5/14/03 |
|--------------------|--|-----------------|---------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English Language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. 1109117_1.DOC